Clinical Trials Browser

OTHER × Immune System Diseases × Plasma cell × Clear all

COVID-19, Immune System Diseases, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03672318 2025-09-16

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

25 enrolled

Plasma cell

Immune System Diseases, Multiple Myeloma

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

10 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Phase 2 Withdrawn

Plasma cell

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

Clinical Trials

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE